April 30th, 2021


R&D grant from AMED for T-ignite cancer immunotherapy.

We have entered into a contract research and development agreement with the Japan Agency for Medical Research and Development (AMED) for a project to develop a nanotechnology-applied cancer immunotherapy as a program of the Creation of Innovative Infrastructure for Clinical Research and Development (CiCLE).